Study shows increased IPL sessions increased response rate of treatment in moderate-to-severe MGD

News
Article

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

Closeup of eyelid inflammation Image Credit: AdobeStock/OHishi_Foto

Image Credit: AdobeStock/OHishi_Foto

A new study reports that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.1 The study was conducted by Yang Lu, MD, first author, and colleagues from the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, and the NHC Key Laboratory of Myopia, Fudan University, both in Shanghai, China.

The clinicians conducted this retrospective study to determine if 90 Asian adult patients with moderate–to–severe MGD could benefit from increasing the number of IPL treatment sessions. Moderate-to-severe MGD is classified as stages 3 to 4.

The patients were divided into 2 groups: 30 patients in group 1 underwent 5 sessions of IPL and 63.3% of them also had expression of the meibomian glands, and 60 patients in group 2 underwent 3 sessions of IPL and 60% also underwent meibomian gland expression.

Results of group comparison

The investigators found that in both groups the symptoms and most clinical indices improved after the IPL treatment sessions finished.

They did not observe a statistical difference in any of the improvement levels of all symptomatic and physical indices, including the ocular surface disease index, tear film break–up time, Demodex, corneal staining, meibum quality, meibomian gland expressibility, and MGD stage (p ≥ 0.05 for all comparisons) between the 2 groups at any time, that is month by month and at the final visit.

However, the investigators did see that the response rate in group 1 after the 5 session of IPL increased compared to the patients in group 2 who were treated with 3 session of IPL treatment (70.0% vs. 63.33%, respectively).

The authors commented, “Increasing the number of IPL sessions is beneficial for patients with moderate-to-severe MGD to increase the response rate of treatment rather than the improvement level. However, there is no need for patients who respond well to a routine number of IPL treatments to undergo additional IPL sessions.”

Reference:
  1. Lu Y, Gong L, Yin Y. Need to increase the number of intense pulsed light (IPL) treatment sessions for patients with moderate to severe meibomian gland dysfunction (MGD). Curr Eye Res. 2024;49:362–367; https://doi.org/10.1080/02713683.2023.2297344
Recent Videos
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, discusses diagnostic confusion that can be encountered when identifying macular edema in patients.
Nate Lighthizer, OD, FAAO, overviews a handful of YAG laser procedures in his AAOpt presentation.
Susan Gromacki, OD, MS, FAAO, FSLS, details a panel that provided a complete course on keratoconus.
© 2024 MJH Life Sciences

All rights reserved.